Aim: In this cohort, we aimed to study the evolution of pregenomic RNA (pgRNA) during treatment and compare it with other disease scores such as FIB-4 and PAGE-B.Methods: Eighty-eight HBeAg negative CHB who received long-term treatment with NAs were included. A quantitative HBV S antigen (HBsAg) assay was performed, and viral HBV DNA was quantified… Continue reading Is there any role for #HBV pgRNA in #fibrosis and #HCC predisposition?
Tag: HBV
Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients
BackgroundEmerging evidence suggests a pivotal role for B-cell responses in the natural history of chronic hepatitis B (CHB). Serum levels of antibodies to HBcAg (anti-HBc) vary across infection stages, but their role in predicting response to antiviral therapy is uncertain. MethodsAnti-HBc levels were assessed before peginterferon (PEG-IFN) therapy in CHB patients who either initiated de… Continue reading Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients
Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients
AbstractBackground & AimsThe hepatitis B virus (HBV) can integrate in the host genome of the hepatocyte and recent findings suggest that integrated HBV contributes to the persistent production of viral proteins. Here we quantified the levels of integrated HBV in chronic hepatitis B (CHB) patients, and analysed the relation between HBV integration, virological activity (plasma… Continue reading Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients
#Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus tenofovir disoproxil fumarate (TDF; 300mg) and aimed to identify the most appropriate dose of pradefovir for the… Continue reading #Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Comparison of Novel Biomarkers with Conventional #HBV Markers among Untreated Adults with Chronic #Hepatitis B in North America
The clinical utility of two novel biomarkers, hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg), as compared to conventional markers of HBV replication and disease activity is unclear. Untreated participants in the North American Hepatitis B Research Network Adult Cohort Study were categorized by chronic hepatitis B (CHB) phases based on HBsAg… Continue reading Comparison of Novel Biomarkers with Conventional #HBV Markers among Untreated Adults with Chronic #Hepatitis B in North America
Serum hepatitis B #core‐related antigen level stratifies risk of disease progression in chronic #hepatitis B patients with intermediate viral load
Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.. ..A total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were… Continue reading Serum hepatitis B #core‐related antigen level stratifies risk of disease progression in chronic #hepatitis B patients with intermediate viral load
Hepatic decompensation in #cirrhotic patients receiving antiviral therapy for chronic #hepatitis B
It is unclear if anti-hepatitis B virus (HBV) treatment can eliminate incident hepatic decompensation. Here we report the incidence and predictors of hepatic decompensation among cirrhotic patients receiving antiviral therapy for chronic hepatitis B.. ..818 patients (mean age, 54.9 years; 519 male [63.4%]) were included in the final analysis. During a mean follow-up of 58.1… Continue reading Hepatic decompensation in #cirrhotic patients receiving antiviral therapy for chronic #hepatitis B
Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs
The purpose of this study was to analyze the clinical characteristics of chronic hepatitis B (CHB) cured by antiviral therapy.. ..The combined treatment time for all participants was 124.7 ± 58.8 weeks, and the average Peg-IFN treatment time was 102.6 ± 56.1 weeks. At 24 weeks, Hepatitis B surface antigen (HBsAg) and Hepatitis B e antigen (HBeAg) had decreased… Continue reading Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs
Unresolved issues of immune tolerance in chronic hepatitis #B
During the natural course of chronic hepatitis B virus infection, immune-tolerant phase is characterized by high viral replication, the presence of HBV e antigen (HBeAg), and normal or minimally elevated serum alanine aminotransferase. Immune-tolerant phase is usually regarded as a benign course of the disease. International guidelines recommend observation rather than treatment during immune-tolerant phase.… Continue reading Unresolved issues of immune tolerance in chronic hepatitis #B
2 Medical News 